On November 6, 2025 Defence Therapeutics Inc. ("Defence" or the "Company"), a leading biotechnology company pioneering next-generation antibody-drug conjugate ("ADC"), reported the successful presentation of new data on its proprietary Accum platform at the 16th World ADC Conference in San Diego, USA (November 4–5, 2025).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation generated exceptional interest from both the scientific and industry communities, with attendees continuing discussions around Defence’s poster long after the official session concluded. The results presented by Dr. Maxime Parisotto, Chief Scientific Officer of Defence Therapeutics, demonstrated how Accum enhances intracellular delivery and payload release, thereby amplifying the potency and therapeutic index of ADCs.

"The response to our new data was phenomenal," said Dr. Parisotto. "It’s clear that the Accum platform addresses one of the key challenges in ADC design—efficient endosomal escape and payload delivery. We are now moving forward to test Accum across a broader range of on-market and development-stage ADCs to fully explore its potential to improve efficacy and patient outcomes."

The Company is now expanding its collaborative and internal testing programs to include multiple commercial and clinical-stage ADC constructs, aiming to validate Accum as a plug-and-play enhancer for the next generation of targeted cancer therapies.

"Our goal is to demonstrate that Accum can universally enhance the performance of ADCs, regardless of the payload or antibody used," said Dr. Mark Lambermon, Head of Quality and Operation at Defence Therapeutics who was also in attendance in San Diego. "We are engaging with leading industry partners to accelerate these evaluations and bring this transformative technology closer to patients."

The Defence team extends its gratitude to the organizers of the World ADC Conference and to the many collaborators and industry partners who joined discussions in San Diego.

(Press release, Defence Therapeutics, NOV 6, 2025, View Source;utm_medium=rss&utm_campaign=defence-announces-successful-presentation-at-the-world-adc-conference-in-san-diego-and-plans-to-expand-evaluation-of-accum-in-commercial-and-pipeline-adcs [SID1234659634])

On November 6, 2025 Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, reported new data demonstrating that its Guardant Reveal blood test helps clinicians to assess the effectiveness of chemotherapy in patients with advanced solid tumors months earlier than conventional methods. This is the first robust clinical validation study of pan-cancer chemotherapy monitoring, published in the Journal of Liquid Biopsy. The study used a tissue-free, methylation-based ctDNA tumor fraction signal to track changes in cancer over time and provides real-world evidence that changes detected in a blood-based tumor signal correlate strongly with patient outcomes, offering oncologists a timely and non-invasive tool for monitoring cancer therapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The study showed that any decrease in tumor fraction signal after chemotherapy initiation was associated with both longer treatment duration and increased survival rates. Notably, patients who experienced a greater than 98% reduction in the tumor signal saw the most significant benefits. Conversely, a rise in the tumor signal identified disease progression up to 18 months earlier with a median lead time of 2.3 months – much earlier than standard clinical measures could detect.

"This study demonstrates the potential of a blood test to give oncologists an earlier and accurate look at whether chemotherapy is helping," said Dr. Craig Eagle, Guardant Health Chief Medical Officer. "Guardant Reveal’s ability to detect molecular changes weeks or months before they show up on scans give doctors more time to adjust care and potentially spare patients from the toxicity of ineffective treatment."

The majority of patients with metastatic solid tumors receive chemotherapy at some point during their treatment. Guardant Reveal interrogates nearly 30,000 methylated regions across the genome resulting in unparalleled precision for tracking and monitoring tumor burden in patients. Because the methylation-based tumor fraction test doesn’t require tumor tissue, Guardant Reveal can be used more broadly to monitor treatment response across multiple cancer types.

(Press release, Guardant Health, NOV 6, 2025, View Source [SID1234659620])

On November 6, 2025 Vizgen, Inc., a spatial multi-omics innovator accelerating biological discovery and new drug development, reported that it will present new spatial multi-omics data at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 40th Annual Meeting on November 7-10, 2025 in National Harbor, Maryland. The company will showcase how researchers can generate a combination of high-quality RNA and protein data via Vizgen’s bioinformatics technology.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Vizgen combined results from MERFISH 2.0 gene expression data generated on the MERSCOPE Ultra with data collected from InSituPlex (ISP) multiplex immunofluorescence (mIF) in sequential sections to decode the complexity of the tumor-immune microenvironment (TiME). In its session on November 7th at SITC (Free SITC Whitepaper), Vizgen will delve into how to co-register two established high-quality datasets to fuel multi-omic research.

"Vizgen is empowering researchers to use the power of spatial multi-omics to gain valuable new insights, and we’re excited to share the latest data at SITC (Free SITC Whitepaper) to demonstrate what is possible to significantly advance research," said Jiang He, VP & Portfolio Owner, Reagents & Sci. Affairs, at Vizgen. "The scientific community in attendance at SITC (Free SITC Whitepaper) 2025 will get a first look at data that improves the understanding of the tumor-immune microenvironment through a unified approach with spatial multi-omics. Vizgen offers a complete solution to study the tumor microenvironment."

POSTERS
Details of the posters at the Gaylord National Resort and Convention Center at SITC (Free SITC Whitepaper) 2025 are as follows:

Abstract Number: 101
Title: Combining Vizgen’s MERSCOPE gene expression profiling and InSituPlex multiplex immunofluorescence (mIF) to reveal functional compartmentalization within the tumor microenvironment (TME)
Session Date: Friday, November 7, 2025
Session Time: Between 12:15 p.m. and 1:45 p.m. ET (Lunch session) and between 5:35 p.m. and 7 p.m. (PM reception)
Presenter: Angela Vasaturo, Director of Scientific Affairs at Vizgen

Abstract Number: 102
Title: New developments in spatial transcriptomics using MERFISH 2.0 unlock insights into the tumor microenvironment
Session Date: Saturday, November 8, 2025
Session Time: Between 12:15 p.m. and 1:45 p.m. ET (Lunch session) and between 5:35 p.m. and 7 p.m. (PM reception)
Presenter: Amanda Burke, PhD, Field Application Scientist, Vizgen

Abstract Number: 84
Title: Enabling scalable tumor microenvironment (TME) profiling with 8-plex InSituPlex multiplex immunofluorescence (mIF) on ZEISS Axioscan 7 spatial biology
Session Date: Saturday, November 8, 2025
Session Time: Between 12:15 p.m. and 1:45 p.m. ET (Lunch session) and between 5:10 p.m. and 6:35 p.m. (PM reception)
Presenter: Kevin Hwang, Ph.D., Senior Scientist, Research at Vizgen

Abstract Number: 88
Title: Establishing a robust and reproducible automated mIF workflow for spatial biology using ZEISS SlideStream and Ultivue by Vizgen’s InSituPlex assays
Session Date: Saturday, November 8, 2025
Session Time: Between 12:15 p.m. and 1:45 p.m. ET (Lunch session) and between 5:35 p.m. and 7 p.m. (PM reception)
Presenter: Cassandra Kysilovsky, Ph.D., Associate Scientist at Vizgen

In exhibit hall booth #838, Vizgen representatives will be showcasing a spatial multi-omic workflow that combines spatial transcriptomics, spatial proteomics, and AI-enhanced data science.

(Press release, Vizgen, NOV 6, 2025, View Source [SID1234659619])

On November 6, 2025 AbCellera (Nasdaq: ABCL) reported financial results for the third quarter of 2025. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"AbCellera successfully delivered on two corporate priorities this quarter by starting activities at our new clinical manufacturing facility and substantially completing our platform investments," said Carl Hansen, Ph.D., founder and CEO of AbCellera. "We ended the quarter with approximately $680 million dollars in available liquidity to execute on our strategy and will continue to prioritize advancing our two lead programs through Phase 1 clinical studies and building our pipeline."

Q3 2025 Business Summary

Generated a net loss of $57.1 million, compared to a net loss of $51.1 million in 2024.
Expanded the leadership team with the appointment of Sarah Noonberg, M.D., Ph.D., as Chief Medical Officer.
ABCL635 and ABCL575 continue to progress through Phase 1 clinical trials.
Reached a cumulative total of 103 partner-initiated program starts with downstreams.
Key Business Metrics

Cumulative Metrics

September 30, 2024

September 30, 2025

Change %

Partner-initiated program starts with downstreams

95

103

8

%

Molecules in the clinic

14

18

29

%

AbCellera started discovery on an additional partner-initiated program with downstreams to reach a cumulative total of 103 partner-initiated program starts with downstreams in Q3 2025 (up from 95 on September 30, 2024). AbCellera and its partners have advanced a cumulative total of 18 molecules into the clinic (up from 14 on September 30, 2024).

Discussion of Q3 2025 Financial Results

Revenue – Total revenue was $9.0 million, compared to $6.5 million in Q3 2024.
Research & Development (R&D) Expenses – R&D expenses were $55.0 million, compared to $41.0 million in Q3 2024. A greater proportion of R&D expenses are used on internal programs, including $15.0 million of specific investments in two internal programs in the third quarter.
Sales & Marketing (S&M) Expenses – S&M expenses were $2.9 million, compared to $3.1 million in Q3 2024.
General & Administrative (G&A) Expenses – G&A expenses were $22.1 million, compared to $19.1 million in Q3 2024.
Net Loss – Net loss of $57.1 million, or $(0.19) per share on a basic and diluted basis, compared to net loss of $51.1 million, or $(0.17) per share on a basic and diluted basis, in Q3 2024.
Liquidity – $523 million of total cash, cash equivalents, and marketable securities and approximately $159 million in available non-dilutive government funding, bringing total available liquidity to approximately $680 million to execute on AbCellera’s strategy.
Conference Call and Webcast

AbCellera will host a conference call and live webcast to discuss these results today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time).

The live webcast of the earnings conference call can be accessed on the Events and Presentations section of AbCellera’s Investor Relations website. A replay of the webcast will be available through the same link following the conference call.

(Press release, AbCellera, NOV 6, 2025, View Source [SID1234659618])

On November 6, 2025 AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, reported that Eric Easom, Co-Founder, Chairman, President and CEO, will participate in a fireside chat at the 8th Annual Evercore HealthCONx Conference being held from December 2-4, 2025.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the event are as follows:

Eric Easom, Co-Founder, Chairman, President and CEO, will participate in a fireside chat on Wednesday, December 3, 2025 at 10:50 AM ET, and members of management will be available for 1X1 meetings.

A webcast can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com. An archived replay will be available for at least 30 days following the presentation.

(Press release, AN2 Therapeutics, NOV 6, 2025, View Source [SID1234659617])